Table 1.
A summary for anti-cancer drugs that easily develop resistance.
| Anti-Cancer Drugs | Indicated Cancers |
|---|---|
| Chemotherapeutic drugs | |
| Cisplatin | Gastric cancer |
| Breast cancer | |
| Head and neck squamous cell carcinoma | |
| Gastric cancer | |
| Esophageal squamous cell carcinoma | |
| Pleural mesotheliom | |
| Glioblastoma | |
| Osteosarcoma | |
| Ehrlich ascites carcinoma | |
| Hepatocellular carcinoma | |
| Ovarian cancer | |
| Paclitaxel | Breast cancer |
| Glioma | |
| Hepatocellular carcinoma | |
| Osteosarcoma | |
| Ovarian cancer | |
| Lung cancer | |
| Colorectal cancer | |
| Gemcitabine | Pancreatic cancer |
| Hepatocellular carcinoma | |
| Doxorubicin | Gastric cancer |
| Breast cancer | |
| Esophageal cancer | |
| Prostate cancer | |
| Bladder cancer | |
| Osteosarcoma | |
| Prostate cancer | |
| Multiple myeloma | |
| Soft tissue sarcoma | |
| Hepatocellular carcinoma | |
| Colorectal cancer | |
| Etoposide | Gastric cancer |
| Glioma | |
| Irinotecan | Colorectal cancer |
| 5-fluorouracil | Colorectal cancer |
| Gastric cancer | |
| Pancreatic cancer | |
| Esophageal cancer | |
| Hepatocellular carcinoma | |
| Oxaliplatin | Colorectal cancer |
| Gastric cancer | |
| Prostate cancer | |
| Hepatocellular carcinoma | |
| Temozolomide | Glioblastoma/Glioma |
| Oligodendroglioma | |
| Vincristine | Acute lymphoblastic leukemia |
| Gastric cancer | |
| Oral epidermoid carcinoma | |
| Colorectal cancer | |
| Carboplatin | Ovarian cancer |
| Adriamycin | Breast cancer |
| Gastric cancer | |
| Osteosarcoma | |
| Glioma | |
| Burkitt lymphoma | |
| B-cell lymphoma | |
| Cytarabine | Burkitt lymphoma |
| B-cell lymphoma | |
| Staurosporine | Pancreatic cancer |
| Mitomycin C | Hepatocellular carcinoma |
| Camptothecin | Hepatocellular carcinoma |
| Melphalan | Multiple myeloma |
| Cyclophosphamide | Breast cancer |
| Epirubicin | Breast cancer |
| Molecular targeted inhibitors | |
| Sorafenib | Hepatocellular carcinoma |
| Tocilizumab | Ovarian cancer |
| Gefitinib | Lung cancer |
| Glioblastoma | |
| Breast cancer | |
| Trastuzumab | Breast cancer |
| Rituximab | Chronic lymphoblastic leukemia |
| B-cell lymphoma | |
| Cetuximab | Oral squamous cell carcinoma |
| Rapatinib | Breast cancer |
| Sunitinib | Renal cell carcinoma |
| Lapatinib | Breast cancer |
| Afatinib | Lung cancer |
| Bevacizumab | Lung cancer |
| Immune checkpoint inhibitors | |
| Nivolumab | Lung cancer |
| Melanoma | |
| Pembrolizumab | Lung cancer |
| Melanoma | |
| Colorectal cancer | |
| Cervical cancer | |
| Atezolizumab | Lung cancer |
| Ipilimumab | Melanoma |
| Lung cancer | |
| Gastro-esophageal cancer | |
| Tremelimumab | Lung cancer |
| Gastro-esophageal cancer | |
| Tislelizumab | Melanoma |
| Lung cancer | |
| Others | |
| Lenalidomide | Multiple myeloma |
| Bortezomib | Breast cancer |
| Multiple myeloma | |
| Tamoxifen | Breast cancer |
| Dexamethasone | Chronic lymphocytic leukemia |